Unravelling Biologics:
How Multi-Dimensional LC-MS is Changing the Game

Biopharmaceuticals such as monoclonal antibodies and therapeutic enzymes are molecular giants, highly heterogeneous and structurally complex. Their safety and efficacy hinge on critical quality attributes (CQAs) like size heterogeneity, charge variants and glycosylation. Understanding these attributes in detail is essential, yet traditional analytical workflows often involve multiple offline steps, lengthy turnaround times, and risk of method artefacts. Recent studies done by our scientists and partners demonstrate how multi-dimensional liquid chromatography coupled to mass spectrometry (mD-LC-MS) is redefining biologics characterization, delivering structural and functional insights in a single, automated workflow.

1. Automated Multi-Dimensional LC-MS: Structural and Functional Insights at Record Speed

A fully automated mD-LC-MS platform integrates multiple chromatographic modes (cation exchange, size exclusion, hydrophobic interaction) with parallel middle-up and bottom-up MS acquisition is shown in the figure below. This enables simultaneous assessment of charge, size, and hydrophobic variants, while providing peptide-level detail on post-translational modifications (PTMs) such as oxidation, deamidation and glycosylation.

Compared to classical offline approaches, this workflow:

  • Reduces analysis time from ~140 hours to ~20 hours;
  • Cuts sample requirements by two orders of magnitude;
  • Minimizes user intervention and artefacts.

More importantly, the setup can link structural heterogeneity to functional behaviour, which in turn drives stability and formulation strategies.

(A) mD-LC-MS configuration incorporating ¹D multi-method option (CEX/SEC/HIC) by means of a column selector valve and ¹D peak collection using MHC; ²D RPLC based desalting, denaturation, reduction and middle-up MS analysis; ³D trypsin digestion; ⁴D RPLC-MS based bottom-up analysis. (B) ¹D CEX, SEC and HIC chromatograms of Fc fragment (sample A) and time schedule showing the collection of a blank cut and five ¹D CEX peaks and subsequent middle-up (yellow) and bottom-up (green) MS analysis. Deck A to B refers to the switch between the 2D-LC MHC valves. Deck A and B are each equipped with 6 loops (40 µL).

2. Methionine Oxidation: A Silent Saboteur

Oxidation of methionine residues in the Fc region is a well-documented risk during manufacturing and storage of an antibody. These residues lie at the CH2-CH3 interface which are critical for FcRn binding. Our study confirms that:

  • Single oxidation at M253 already compromises FcRn-antibody interaction;
  • Combined oxidation of M253 and M429 exacerbates the effect;
  • Variants oxidized on both heavy chains exhibit the most severe loss of binding.

This structural insight translates into functional consequences: reduced FcRn binding means faster clearance and shorter therapeutic half-life.

Correlation between FcRn binding ELISA data of offline collected charge variants and ²D FcRn data obtained by online 2D-CEX-FcRn-MS. Colors are representative of a given stress condition.

3. Glyco-Engineering: Boosting Enzyme Uptake by 20×

For lysosomal enzymes like recombinant human acid α-glucosidase (rhGAA), glycosylation is more than decoration: it dictates cellular uptake. Mannose-6-phosphate (M6P) residues act as molecular “zip codes” directing enzymes to lysosomes. Using comprehensive 2D-LC×LC-MS, our team mapped site-specific glycosylation of rhGAA and compared first-generation CHO-derived products with next-generation yeast-engineered variants. Our findings:

  • CHO-derived rhGAA carries limited M6P, restricting its cellular uptake.
  • Yeast-engineered rhGAA exhibits phosphorylated high-mannose glycans at all seven N-glycosylation sites.
  • Result: a 20-fold higher uptake in Pompe patient fibroblasts of glyco-engineered rhGAA, showing how analytics can guide biotherapeutic design.

LC×LC–MS peptide map of (a,c,e,g) first- and (b,d,f,h) next-generation glyco-engineered rhGAA digest. (a-b) Full MS data; (c-d) all-ion fragmentation data extracting the sugar oxonium ions at m/z 204.0867 for N-acetylglucosamine-GlcNAc; (e-f) m/z274.0921 for N-acetylneuraminic acid-NeuAc; (g-h) m/z 243.0264 for mannose-6-phosphate–Man6P. Ions were extracted at 20 ppm mass accuracy. Additional spots revealed in Figure h can be traced back to M6P carrying O-glycosylated peptides.

The Big Picture

Multi-dimensional LC-MS is no longer a luxury. It is the new standard for biologics characterization. By combining deep structural analysis with functional context in a single automated workflow, it can accelerate development timelines, reduce risk and resource consumption, and enable smarter decisions for safer, more effective therapeutics.

Explore the full studies here:

Want to learn more about our advanced analytics? Subscribe to our newsletter below!

* indicates required